<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01385228</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00026577</org_study_id>
    <secondary_id>PZP113296</secondary_id>
    <secondary_id>c09-039</secondary_id>
    <nct_id>NCT01385228</nct_id>
  </id_info>
  <brief_title>Pazopanib, Docetaxel, Prednisone Prostate</brief_title>
  <official_title>Phase I Study of Docetaxel, Prednisone and Pazopanib in Men With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and Poor-Risk Factors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daniel George, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose is to define the safety and tolerability of docetaxel/prednisone in
      combination with pazopanib (DPP) in men with metastatic Castration Resistant Prostate Cancer
      (mCRPC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase I study will consist of a dose escalation portion which includes a dose escalation
      phase of 10 dose levels: (1a) docetaxel 60 mg/m2, pazopanib 400 mg daily, prednisone 5 mg
      BID; (2a) docetaxel 75 mg/m2, pazopanib 400 mg daily, prednisone 5 mg BID; and (3a) docetaxel
      75 mg/m2, pazopanib 600 mg daily, prednisone 5 mg BID; (4a) docetaxel 75mg/m2, pazopanib 800
      mg daily, (5a) docetaxel 75mg/m2, pazopanib 1000mg daily, prednisone 5 mg; (1b) docetaxel 60
      mg/m2, pazopanib 400 mg daily x 17 days, prednisone 5 mg BID; (2b) docetaxel 75 mg/m2,
      pazopanib 400 mg daily x 17 days, prednisone 5 mg BID; and (3b) docetaxel 75 mg/m2, pazopanib
      600 mg daily x 17 days, prednisone 5 mg BID; (4b) docetaxel 75mg/m2, pazopanib 800 mg daily x
      17 days, (5b) docetaxel 75mg/m2, pazopanib 1000mg daily x 17 days, prednisone 5 mg. If the
      investigators see &gt; 1 dose limiting toxicity (DLT) at Dose level 3 then the investigators
      would investigate docetaxel 75 mg/m2, pazopanib 600 mg daily, prednisone 5 mg BID (Dose level
      3a). If &lt; 1 DLT are seen at Dose level 3 and Pharmacokinetic (PK) analysis is complete and
      acceptable, then the investigators will proceed to dose level 4) docetaxel 75 mg/m2,
      pazopanib 1000 mg daily, prednisone 5 mg BID.

      The investigators will dose escalate in a classic 3+3 design. The maximum tolerated dose
      (MTD) will be defined as the highest dose level that does not result in 2 or more dose
      limiting toxicities (DLTs). A dose expansion at the MTD of 10-15 patients (up to a total of
      36 patients) will be accrued in order to further describe the safety profile.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and Percent of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>15 months</time_frame>
    <description>The primary objective for the phase I study is to assess the safety and tolerability of pazopanib, docetaxel, and prednisone given in combination in patients with metastatic castration resistant prostate cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Establish the maximum tolerated dose</measure>
    <time_frame>15 months</time_frame>
    <description>Determine the dose levels of pazopanib and docetaxel that are the most tolerated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Establish the optimal dosing schedule</measure>
    <time_frame>15 months</time_frame>
    <description>Establish the optimal dosing schedule for the combination of docetaxel, prednisone and pazopanib</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Dose Level &quot;Xa&quot;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily pazopanib for Days 1-21 in combination with docetaxel given IV on Day 1 and prednisone daily. Pegfilgrastim (Neulasta) every 21 days on Day 2, 3 or 4 of each cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level &quot;Xb&quot;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily oral administration of pazopanib for Days 3-19 in combination with docetaxel given intravenous administration on Day 1 and prednisone daily. Pegfilgrastim (Neulasta) every 21 days on Day 2, 3 or 4 of each cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib</intervention_name>
    <description>Dose Level &quot;Xa&quot; - daily administration of pazopanib on days 1 through 21 starting at 400mg with a maximum dose of 1000mg.</description>
    <arm_group_label>Dose Level &quot;Xa&quot;</arm_group_label>
    <other_name>Pazopanib (GW786034)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel given IV on Day 1 starting dose 60mg/m2 increase to 75mg/m2</description>
    <arm_group_label>Dose Level &quot;Xa&quot;</arm_group_label>
    <arm_group_label>Dose Level &quot;Xb&quot;</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib</intervention_name>
    <description>Dose Level &quot;Xb&quot; - daily administration of pazopanib on days 3 through 19 starting at 400mg with a maximum dose of 1000mg.</description>
    <arm_group_label>Dose Level &quot;Xb&quot;</arm_group_label>
    <other_name>Pazopanib (GW786034)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>5mg Prednisone given twice daily days 1-21.</description>
    <arm_group_label>Dose Level &quot;Xa&quot;</arm_group_label>
    <arm_group_label>Dose Level &quot;Xb&quot;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegfilgrastim</intervention_name>
    <arm_group_label>Dose Level &quot;Xa&quot;</arm_group_label>
    <arm_group_label>Dose Level &quot;Xb&quot;</arm_group_label>
    <other_name>Neulasta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed carcinoma of the prostate. Histologic evidence may be
             confirmed through local or metastatic biopsy review. Non-adenocarcinomas are
             permitted.

          -  Radiographic evidence of metastatic disease; non-evaluable, bone only metastasis is
             permitted.

          -  Evidence of disease progression despite castrate levels of testosterone (&lt;50 ng/dl).

          -  At the time of screening, at least 2 weeks since prior palliative radiation therapy
             and 4 weeks from major surgery, and resolution of all toxic effects of prior therapy
             to National Cancer Institute Common Terminology Criteria for Adverse Events
             (NCI-CTCAE); version 4.0 Grade &lt; 1.

          -  Age &gt;18 years

          -  Adequate laboratory parameters

          -  Eastern Cooperative Oncology Group (ECOG) performance status between 0 and 2

          -  Life expectancy greater than 3 months

          -  Written, signed and dated Institutional Review Board (IRB) approved informed consent
             form.

        Exclusion Criteria:

          -  History of or active central nervous system metastases

          -  The use of immunologic, biologic, or hormonal therapies within 2 weeks of study entry.

          -  Major surgery, open biopsy, traumatic injury within 4 weeks of the screening visit

          -  Subjects who have not recovered from prior biopsy, surgery, traumatic injury, and/or
             radiation therapy.

          -  Previous treatment with docetaxel, including in the neo-adjuvant or adjuvant setting

          -  Presence of non-healing wound or ulcer

          -  Grade 3 or greater hemorrhage within the past month.

          -  Uncontrolled hypertension

          -  American Heart Association Class 2-4 heart disease or any history of congestive heart
             failure with an ejection fraction &lt;40%, recent cardiovascular event (within 12 months)
             including unstable angina, any exertional angina, myocardial infarction, exertional or
             rest claudication, or stroke/Cerebral Vascular Event/Transient Ischemic Attack.
             Patients with known moderate to severe documented carotid or peripheral vascular
             disease are excluded. Angioplasty or stenting of coronary or peripheral arteries are
             exclusionary if within the past 12 months.

          -  Anticoagulation with warfarin (therapeutic doses of warfarin for catheter patency are
             permitted up to 2 mg/day). Low molecular weight heparin is permitted.

          -  Diabetes mellitus with glycosylated hemoglobin A1c (HbgA1c) &gt; 8% despite therapy

          -  Subjects with active autoimmune disorder(s) being treated with systemic
             immunosuppressive agents within 4 weeks prior to the screening visit.

          -  Active infection(s), active antimicrobial therapy or serious intercurrent illness.

          -  Does not agree to use medically acceptable contraceptive methods while on study and
             for 3 months after the last dose of pazopanib.

          -  Any other major medical or psychiatric illness that, in the investigator's judgment,
             will substantially increase the risk associated with the subject's participation in
             this study, including inability to absorb oral medications.

          -  Known hypersensitivity to any of the components in the docetaxel infusion or other
             medical reasons for not being able to receive adequate premedication (for example,
             antihistamine or anti-inflammatory agents).

          -  CalculatedQT (QTc) interval on baseline EKG &gt; 500milliseconds

          -  History or presence of nephrotic syndrome
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel J George, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2011</study_first_submitted>
  <study_first_submitted_qc>June 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2011</study_first_posted>
  <last_update_submitted>April 3, 2017</last_update_submitted>
  <last_update_submitted_qc>April 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Daniel George, MD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <keyword>metastatic</keyword>
  <keyword>pazopanib</keyword>
  <keyword>docetaxel</keyword>
  <keyword>metastatic prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

